Pyrazolotriazine CDK7 Inhibitors for Selective Cell Cycle Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases, and infectious diseases lack effective inhibitors targeting cyclin-dependent kinase 7 (CDK7), which is crucial for cell cycle progression and transcription regulation, leading to limited therapeutic options and potential drug resistance in viral infections.
Innovation Solution
Development of pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and their pharmaceutically acceptable salts that act as selective inhibitors of CDK7, modulating cell cycle and transcription processes to treat these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current treatments for cell proliferative diseases are used, then existing therapeutic options are available, but effective inhibitors targeting CDK7 are lacking leading to limited therapeutic options and potential drug resistance
Solution Approach 1:
The patent develops novel pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivative compounds with specific molecular structures designed to target CDK7. These compounds represent a parameter change in chemical structure and mechanism of action compared to existing treatments, providing new therapeutic options that effectively inhibit CDK7 without inducing drug resistance
Solution Approach 2:
The patent introduces CDK7 inhibitors as intermediary compounds that mediate the therapeutic effect by selectively blocking CDK7 activity. These compounds act as intermediaries between the administration route and the target biological processes (cell cycle progression and transcription regulation), providing a new mechanism for treating proliferative and inflammatory diseases
2Reliability
If CDK7 inhibitors are developed to target cell cycle progression and transcription regulation, then therapeutic benefits are achieved, but selectivity among multiple CDK family members must be maintained
Solution Approach 1:
The patent designs compounds with specific local structural features (pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine cores with particular substituent patterns) that provide selective binding to CDK7. The local chemical environment and spatial arrangement of functional groups in these compounds are optimized to interact specifically with CDK7's active site, achieving therapeutic efficacy while minimizing off-target effects on other CDK family members
Data Source
AI summary
The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives having Formula I:and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.